Resources

Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline.

In this blog, BIA member Brainomix, following its series C round, answers questions on the company's origins and future trajectory.

Aseda Sciences is a leading global innovator in generating, analysing and visualising high-quality predictive small molecule data.

A new partnership with ARC West London, designed to support innovators across AI, life sciences, robotics and digital industries to scale, bolstering the West London life sciences ecosystem.

University of Oxford spinout accelerates commercial expansion in the US of its innovative stroke AI imaging solution, with its demonstrated impact on vital treatments.

TechBio's 2024 breakthroughs proved it’s not just innovating—it’s transforming healthcare, with the UK leading the charge into a future where biology, tech, and data redefine possibilities.

New legislation was laid in Parliament last Thursday to modernise the regulation of clinical trials in the UK.

As 2024 comes to a close, we’re proud to reflect on a year of championing the life sciences sector, from driving impactful policy changes to fostering connections across the UK and beyond. Dive into our key achievements, events, and milestones that shaped the year and set the stage for an exciting 2025.

Today, deepmirror has raised $2.4 million to simplify the adoption of AI for molecule design and enable every company to get drugs to patients faster with their accessible AI-powered platform.

The Innovation Ecosystem Programme, an 18-month-long NHS England project, which the BIA have been involved in throughout, describes how the UK can lead the way globally in health gains and life sciences powered growth. Its final report was published last week.

MultiOmic Health, a leading AI-enabled drug discovery company, announces the identification of novel patient endotypes and the development of proprietary biomarkers for stratifying diabetic kidney disease (DKD) patients.

New data shows investing in life sciences produces great returns, London Life Sciences Week and #bioProcessUK are nearly here.

Attending the BIA’s TechBio UK conference this year offered an incredible opportunity to witness the ingenuity and innovation driving the future of life sciences.

Read today's blog to learn about our latest reports, upcoming events and our CEO's thoughts on the upcoming budget.

The UK is a global leader in TechBio, drawing substantial investments and nurturing a vibrant ecosystem of talent and businesses, reveals a report launched today by the BIA.